Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-217 in Essential Tremor
NCT02978781Phase 2Completed
- Sponsor
- Biogen
- Start
- Mar 2017
- Primary completion
- Nov 2017
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zuranolone in essential tremor (ET) (5 arms), sponsored by Biogen. Primary endpoint: Change From Baseline/Randomization in Accelerometer-based Kinesia Kinetic Tremor Combined Score at Day 15. Started Mar 2017; status: completed.
02
Drugs
zuranolone
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on NCT02978781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978781.